CA-VIZ.AI
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of VizTM Vascular Suite, AI-powered software enabling vascular care teams to automatically detect and triage care for suspected pulmonary embolism, right heart strain, aortic dissection, and abdominal aortic aneurysm (AAA).1 Viz.ai submitted a new 510(k) application to the U.S. Food & Drug Administration (FDA) for the AAA algorithm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005812/en/
Viz™ Vascular Suite (Photo: Business Wire)
“Recognizing the symptoms of serious vascular conditions, such as aortic dissections, is hugely important because any delay in treatment can have a direct impact on patient outcomes,” said Philip Batista, MD, Associate Program Director, Vascular and Endovascular Surgery Residency, Cooper. “When Viz identifies an abnormal scan, it quickly notifies the appropriate specialists regardless of their location, facilitating seamless communication via mobile application. We’ve been using the Viz software for the last several months and have seen improvements in patient care across our institution.”
The Viz Vascular Suite uses artificial intelligence to automatically analyze an array of imaging modalities, including computerized tomography (CT), electrocardiogram (ECG), and more for suspected vascular diseases. If a suspected pathology is found, the app automatically alerts and displays high-fidelity patient scans on providers’ mobile devices. Clinicians can use Viz Vascular Suite to remotely coordinate vascular pathology care within a hospital system’s hub and spoke network and enable synchronous, HIPAA-compliant communication among specialists. The platform is enhanced by AI for immediate team activation and facilitates informed, efficient treatment decisions.
“We set out to build a solution where any patient with life threatening diseases can benefit from AI-powered care coordination with triage and real-time mobile communication. The Viz Vascular Suite will bring the advantages of intelligent care coordination to even more patients and help clinical teams achieve better clinical outcomes,” said Chris Mansi, CEO of Viz.ai. “The feedback from our early adopters has been highly positive, and we look forward to expanding access to this solution to our over 1,300 hospital customer base.”
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
1 Suspected abdominal aortic aneurysm is 510(k) pending. Not available for sale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005812/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release Fourth Quarter & Full Year 2025 Results on Feb. 11, 2026; IFF to Present at 2026 CAGNY Conference on Feb. 19, 202621.1.2026 22:15:00 CET | Press release
IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2025 earnings results following the market close on Wednesday, Feb. 11, 2026. The management team will host a live webcast on Thursday, Feb. 12, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company’s management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 19, 2026 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and en
UAE Research Program for Rain Enhancement Science Announces Awardees of 6th Cycle Grants21.1.2026 21:17:00 CET | Press release
The UAE Research Program for Rain Enhancement Science (UAEREP), managed by the National Center of Meteorology (NCM), announced the awardees of its Sixth Cycle research grants. Each recipient will receive up to US$1.5 million over three years, with a maximum annual allocation of US$550,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121231610/en/ UAE Research Program for Rain Enhancement Science Announces Awardees of 6th Cycle Grants (Photo: AETOSWire) The Sixth Cycle awardees are Dr. Dixon Michael, Principal Radar Meteorologist and Software Engineer at Echo Science Works, USA, for “Advancing Cloud Seeding Science with Dual-Polarization Radar Signatures and AI”; Prof. Linda Zou, Adjunct Professor at Victoria University, Australia, for “AI-assisted Development and Optimization of Glaciogenic Cloud Seeding Materials”; and Dr. Oliver Branch, Senior Scientist at the University of Hohenheim, Germany, for “Rainfall Enhanceme
Logical Intelligence Introduces First Energy-Based Reasoning AI Model, Signals Early Steps Toward AGI, Adds Yann LeCun and Patrick Hillmann to Leadership21.1.2026 19:21:00 CET | Press release
Logical Intelligence, an artificial intelligence company developing energy-based (EBM) reasoning systems, today announced that Kona 1.0, its pioneering EBM for reasoning, will enter pilot programs with select partners in the energy, advanced manufacturing, and semiconductor industries later this quarter. Logical Intelligence also released a live demonstration of Kona 1.0 on its website, beginning with head-to-head sudoku challenges against leading large language models. Additional demonstrations, including chess and Go, are planned. The company said the goal is to give researchers and the public a clear view into how energy-based reasoning differs from probabilistic systems. “Kona learns by recognizing and correcting its own mistakes, rather than guessing the most likely answer,” said Eve Bodnia, founder and CEO of Logical Intelligence. “If general intelligence means the ability to reason across domains, learn from error, and improve without being retrained for each task, then we are s
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership21.1.2026 17:35:00 CET | Press release
Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tribunal. This decision has no impact on the commercialization of Galderma’s neuromodulator portfolio. Galderma will continue to commercialize and supply Dysport®/Azzalure®, Alluzience®, and RelfydessTM in all territories where it has regulatory approval and in accordance with our existing agreements with our partner Ipsen. Progressing on our path towards becoming the undisputed dermatology powerhouse Galderma remains focused on its ambition to become the world’s undisputed dermatology powerhouse across the full spectrum of a fast-growi
ThetaRay Appoints Financial Markets Technology Leader Brad Levy as Chief Executive Officer21.1.2026 17:00:00 CET | Press release
Former Symphony CEO to lead ThetaRay’s next phase of AI-driven category leadership in transaction monitoring and due diligence ThetaRay, a global leader in Cognitive AI financial crime compliance, today announced the appointment of Brad Levy as Chief Executive Officer. Levy, a leading financial markets infrastructure executive and former CEO of Symphony, will lead ThetaRay’s next phase of growth as the company continues to scale its Cognitive AI platform, now emerging as the leading AI strategy and technology for transaction monitoring and transaction due diligence, across banks and fintechs worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121002476/en/ ThetaRay Appoints Brad Levy as CEO Levy brings decades of experience building and leading mission-critical financial infrastructure at scale. Most recently, he served as CEO of Symphony, the financial markets infrastructure and technology platform established by a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom